Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C12H17NO3 |
| Molecular Weight | 223.2683 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC1=CC=C(NC(=O)CC(C)O)C=C1
InChI
InChIKey=LIAWQASKBFCRNR-UHFFFAOYSA-N
InChI=1S/C12H17NO3/c1-3-16-11-6-4-10(5-7-11)13-12(15)8-9(2)14/h4-7,9,14H,3,8H2,1-2H3,(H,13,15)
| Molecular Formula | C12H17NO3 |
| Molecular Weight | 223.2683 |
| Charge | 0 |
| Count |
|
| Stereochemistry | RACEMIC |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Optical Activity | ( + / - ) |
DescriptionCurator's Comment: Description was created based on several sources, including
http://www.waters.com/webassets/cms/library/docs/720004141en.pdf | http://www.waters.com/webassets/cms/library/docs/720005475en.pdf | http://journals.sagepub.com/doi/abs/10.1177/009286150103500134
Curator's Comment: Description was created based on several sources, including
http://www.waters.com/webassets/cms/library/docs/720004141en.pdf | http://www.waters.com/webassets/cms/library/docs/720005475en.pdf | http://journals.sagepub.com/doi/abs/10.1177/009286150103500134
Bucetin (3-hydroxy-p-butyrophenetidide) is an antipyretic analgesic drug with cancerogenic potential. Bucetin was withdrawn from the market due to renal toxicity. The compound has the chiral center. Pharmacological activity of enantiomers is unknown. The racemic mixture is used as a model compound to demostrate effectivity of the chiral supercritical fluid chromatography purification.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Study on Butylon, a new combined analgesic, with special reference to the analgesic potentiation between o-ethoxybenzamide and 3-hydroxy-p-burtyrophenetidide (Bucetin)]. | 1966 May 20 |
|
| Studies on absorption and excretion of drug. 8. The release rate in vivo of antipyretic and analgesic drugs from commercial sugar coated tablets. | 1967 Jul |
|
| Drug absorption, metabolism, and excretion. 3. Synthesis of the metabolites of bucetin (beta-hydroxybutyro-p-phenetidide). | 1968 Nov |
|
| Drug absorption, metabolism, and excretion. II. Metabolism of bucetin (beta-hydroxybutyro-p-phenetidide) in rabbits. | 1968 Sep |
|
| Carcinogenicity of bucetin in (C57BL/6 X C3H)F1 mice. | 1987 Nov |
Patents
Sample Use Guides
In Vivo Use Guide
Curator's Comment: The tablet contains bucetin 100 mg, ethoxybenzamide 100 mg, Al-acetylsalicylate 180 mg (https://www.jstage.jst.go.jp/article/cpb1958/15/7/15_7_1002/_pdf)
The tablet contains bucetin 100 mg. The tablets are given to male adults with 200 ml of water on a fasting stomach.
Route of Administration:
Oral
In Vitro Use Guide
Curator's Comment: https://www.jstage.jst.go.jp/article/cpb1958/33/7/33_7_2877/_pdf
Bucetin was found to be mutagenic to Salmonella typhimurum TA100 in the presence of liver 9000g supernatant fraction (S9) prepared from polychlorinated biphenyl (PCB)-treated hamsters and a reduced NADPH-generating system.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 10:19:45 GMT 2023
by
admin
on
Sat Dec 16 10:19:45 GMT 2023
|
| Record UNII |
1Z23WB033I
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1Z23WB033I
Created by
admin on Sat Dec 16 10:19:45 GMT 2023 , Edited by admin on Sat Dec 16 10:19:45 GMT 2023
|
PRIMARY | |||
|
14130
Created by
admin on Sat Dec 16 10:19:45 GMT 2023 , Edited by admin on Sat Dec 16 10:19:45 GMT 2023
|
PRIMARY | |||
|
156674-11-2
Created by
admin on Sat Dec 16 10:19:45 GMT 2023 , Edited by admin on Sat Dec 16 10:19:45 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
